Menu
The Goodman Institute Health Blog
  • Home
  • Authors
    • Devon Herrick, Ph.D.
    • John C. Goodman
  • Popular Topics
    • Hits & Misses
    • Artificial Intelligence and Healthcare
    • Doctors & Hospitals
      • COVID-19 and Public Health
    • Policy & Legislation
      • Affordable Care Act
    • Health Economics & Costs
      • Cost of Healthcare
      • Drug Prices & Regulations
      • Health Reform
    • Health Insurance
      • Public Insurance
      • Medicare
    • Telemedicine
      • Medical Tourism
  • Goodman Institute
  • Contact
  • Search
The Goodman Institute Health Blog

Category: Drug Prices & Regulations

Thursday Links

Posted on January 19, 2023 by John C. Goodman
  • Half of all Medicare beneficiaries are now in Medicare Advantage plans.
  • Gallup: 38% say they or a family member put off medical care because of costs – the highest number in 22 years.
  • Cato: Black civil servants earned approximately 3.4 – 6.9 percentage points less because of the segregationist policies of  Woodrow Wilson – the 20th century’s most prominent “progressive.”
  • Mark Cuban’s online Cost Plus Drug Co. as 2 million customers. Cuban says the pharmacy could have saved his Dallas Mavericks basketball team $146,000. So why didn’t they?
+

Sneaky FDA Tricked Congress to Granting it the Power to Regulate the Practice of Medicine

Posted on January 17, 2023 by Devon Herrick

The U.S. Food and Drug Administration (FDA) is tasked with ensuring the safety and effectiveness of drugs, and medical devices in addition to food and cosmetic safety. One thing the FDA is not responsible for is regulating the practice of medicine. The following is from an FDA Q & A website:

+

New Drug for Obesity May Become Biggest Selling Drug of All Time

Posted on January 6, 2023 by Devon Herrick

A new drug by Eli Lilly is poised to become the biggest selling drug of all time. However, a writer at NBC News is worried about whether Americans can afford it. The drug tirzepatide has completed its final stages of testing and the U.S. Food and Drug Administration is likely to approve it for weight loss in 2023. Tirzepatide is the third drug from a new class of diabetes drugs called GLP-1 agonists, which includes the drugs Wegovy and Saxenda.

+

Friday Links

Posted on January 6, 2023January 5, 2023 by John C. Goodman
  • DOJ: Postal service can deliver abortion pills.
  • NIH-funded food pyramid says lucky charms are better than steak; chocolate covered almonds are better than cheddar cheese.
  • Pro-choice argument: the FDA’s step forward on abortion medications is not nearly good enough.
  • The European Union bans 1,300 ingredients from use in cosmetics. The US bans 11. (NYT)
+
  • Previous
  • 1
  • …
  • 206
  • 207
  • 208
  • 209
  • 210
  • 211
  • 212
  • …
  • 253
  • Next

For many years, our health care blog was the only free enterprise health policy blog on the internet. Then, when the NCPA closed its doors, the health blog stopped as well.

During this five-year hiatus no one else has come forward to claim the space. So, my colleagues and I have decided to restart the blog in connection with the Goodman Institute. We invite you and others to use this forum to share your views.

John C. Goodman,

Visit www.goodmaninstitute.org

Subscribe via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 45 other subscribers

Popular Topics

©2026 The Goodman Institute Health Blog | Website by Lexicom